glp 1 gip triple agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Retatrutide: The triple agonist powering
Description
Conception and design: C
A nationwide register-based cohort and self-controlled case series study
These became widely available through telehealth companies at significantly lower prices
Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function
Josse RG, Majumdar SR, Zheng Y, Adler A, Angelyn Bethel M, Buse JB, et al
BMC Cancer
